3,791 companies
2,409 AI summaries
1,867 risk analyses
1,334 growth scores
Register free — watchlist & alerts →
🔔 Get free email alerts on Nippon Shinyaku Co.,Ltd. (4516)
AI summaries of Japanese EDINET filings — in English. Free, unsubscribe anytime.
- ✓ Email alert when 4516 files its next EDINET disclosure
- ✓ AI summary · sentiment · risk · growth (JA / EN)
- ✓ Free account: watchlist & alerts on all the stocks you follow
EDINET 4516 Positive Risk Analyzed 📈 Growth 7/10
Nippon Shinyaku Co.,Ltd.
Annual Securities Report - 163rd Term(2025/04/01 - 2026/03/31) ／ 2026-06-23 11:26
Covers EDINET statutory filings (TDNET timely disclosures / earnings flashes are not included).
EarningsGuidance UpNew ProductNew MarketBacklogPricing
AI Summary
2026-06-23 11:31
FY2025 revenue +6.6% (¥160.8B→¥170.8B), operating profit +0.1% (¥35.5B) on moderate growth. Uptaravi and Fintepla drove pharmaceuticals +7.1%. FY2026 guidance shows revenue +17.1%, OP +7.1%, with US new product launches and expanded global royalties as key drivers.
KEY POINTS
- Revenue +6.6% to ¥170.8B; pharma segment +7.1% led by Uptaravi and Fintepla strength
- FY2026 guidance: revenue ¥200B (+17.1%), operating profit ¥38.0B (+7.1%) signals upside momentum
- US launch of Deramiocel, Arlyday and expanded royalty streams position global expansion acceleration
📊 Revenue
Revenue +6.6% (¥160.8B → ¥170.8B)
💰 Operating profit
Operating profit +0.1% (¥35.4B → ¥35.5B)
🔮 Outlook
FY2026 revenue ¥200.0B (+17.1%), operating profit ¥38.0B (+7.1%) expected
📈 Growth outlook
📈 Growth 7/10
Targeting double-digit growth through US new product launches (Deramiocel, Arlyday) and expanded overseas royalties to offset Uptaravi patent cliff. 2028 target: revenue ¥230B, OP ¥30B.
Growth drivers
- US launches of Deramiocel, Arlyday, Fintepla, Uptaravi new product portfolio
- Continued royalty expansion from Uptaravi overseas sales
- Accelerated clinical development via global marketing and in/out-licensing
- Expanded rare disease pipeline (DMD, nucleic acid therapeutics)
Risk and growth scores and tags are AI-generated estimates from analyzing the disclosure. They are not guarantees of fact, nor investment advice or recommendations. Make investment decisions at your own discretion.
⚠️ Extracted Risk Factors
| Category | Description | Score | New |
|---|---|---|---|
| Earnings Deterioration Risk | Intense global competition and declining Uptaravi sales would jeopardize patent cliff mitigation strategy and severely impact operating margins. | 8/10 | |
| R&D Risk | Multiple nucleic acid drug programs (DMD, others) face risk of efficacy failures, clinical trial setbacks, and regulatory rejection. | 7/10 | |
| Intellectual Property Risk | Third-party IP litigation, patent invalidation rulings, or damage awards could erode competitive advantage and reduce profitability. | 6/10 | |
| Regulatory Risk | Continued drug price cuts and generic promotion policies could further pressure domestic pharmaceutical revenues and profits. | 6/10 | |
| Talent/Human Capital Risk | Intensifying competition for specialized pharma talent (R&D, global leaders) could slow innovation and development momentum. | 5/10 | |
| Supply Chain Risk | Natural disasters, pandemics, or geopolitical conflicts affecting suppliers or contract manufacturers could disrupt product supply. | 5/10 | |
| Drug Safety Risk | Unexpected serious adverse events in marketed drugs could trigger withdrawal, recalls, and reputational damage. | 5/10 | |
| Foreign Exchange Risk | Foreign exchange fluctuations in USD from overseas sales and royalty income could impact operating profit. | 4/10 |
8/10
Earnings Deterioration Risk
Intense global competition and declining Uptaravi sales would jeopardize patent cliff mitigation strategy and severely impact operating margins.
7/10
R&D Risk
Multiple nucleic acid drug programs (DMD, others) face risk of efficacy failures, clinical trial setbacks, and regulatory rejection.
6/10
Intellectual Property Risk
Third-party IP litigation, patent invalidation rulings, or damage awards could erode competitive advantage and reduce profitability.
6/10
Regulatory Risk
Continued drug price cuts and generic promotion policies could further pressure domestic pharmaceutical revenues and profits.
5/10
Talent/Human Capital Risk
Intensifying competition for specialized pharma talent (R&D, global leaders) could slow innovation and development momentum.
5/10
Supply Chain Risk
Natural disasters, pandemics, or geopolitical conflicts affecting suppliers or contract manufacturers could disrupt product supply.
5/10
Drug Safety Risk
Unexpected serious adverse events in marketed drugs could trigger withdrawal, recalls, and reputational damage.
4/10
Foreign Exchange Risk
Foreign exchange fluctuations in USD from overseas sales and royalty income could impact operating profit.
Track Japanese disclosures with JSIGNAL
AI summaries, risk & growth analysis, watchlist alerts and a screener for every Japanese listed company.
Start free — 30-day trial Login